Richard A. Gonzalez - Feb 17, 2022 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
Chairman of the Board and CEO, Director
Signature
Steven L. Scrogham, attorney-in-fact for Richard A. Gonzalez
Stock symbol
ABBV
Transactions as of
Feb 17, 2022
Transactions value $
$0
Form type
4
Date filed
2/22/2022, 04:32 PM
Previous filing
Dec 10, 2021
Next filing
Mar 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Award $0 +134K +35.55% $0.00 510K Feb 17, 2022 Direct F1
transaction ABBV Common Stock, $0.01 par value Award $0 +29.1K +5.7% $0.00 540K Feb 17, 2022 Direct F2
transaction ABBV Common Stock, $0.01 par value Award $0 +34.9K +6.47% $0.00 575K Feb 17, 2022 Direct F3
transaction ABBV Common Stock, $0.01 par value Award $0 +34.1K +5.94% $0.00 609K Feb 17, 2022 Direct F4
holding ABBV Common Stock, $0.01 par value 17.6K Feb 17, 2022 By Spouse F5
holding ABBV Common Stock, $0.01 par value 5.9K Feb 17, 2022 By Step-daughter F5
holding ABBV Common Stock, $0.01 par value 5.9K Feb 17, 2022 By Step-son F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right To Buy) Award $0 +158K $0.00 158K Feb 18, 2022 Common Stock 158K $144.54 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F2 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F3 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F4 Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022.
F5 The reporting person disclaims beneficial ownership of these securities.
F6 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 52,540 on February 17, 2023, 52,539 on February 17, 2024, and 52,539 on February 17, 2025.